Device Trial Radar · NCT06668402
Study of Daily Step Count and Treatment Response in Rectal Cancer (STEP-R)
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Oct 30, 2024
Primary completion
May 15, 2026
Study completion Sep 5, 2026
Sponsor
- Lead sponsor
- Gazi UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 31, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to examine the impact of daily physical activity, specifically step count, on treatment outcomes and side effects in patients with locally advanced rectal cancer receiving total neoadjuvant therapy (chemotherapy and radiotherapy before surgery). Using Huawei Watch Fit 2 smartwatches, we will track participants' daily step counts, heart rate, and sleep quality. The primary hypothesis is that higher step counts and physical activity levels correlate with higher rates of complete pathological response at surgery. A secondary hypothesis is that increased physical activity may be associated with fewer or less severe side effects during treatment. Participants will wear a smartwatch and complete the EORTC QLQ-C30 Quality of Life Questionnaire and the Pittsburgh Sleep Quality Index at the beginning and end of treatment. Data from the smartwatch, including step count, heart rate changes, and sleep duration, will be reviewed weekly during routine visits. Approximately 200 patients with rectal cancer will participate, and each will be followed from the start of therapy until surgery (around 4-6 months). Total data collection is expected to take 12-15 months. This study could improve cancer care by identifying links between physical activity and treatment outcomes, supporting future exercise guidelines for oncology patients.
Conditions
- Exercise
- Total Neoadjuvant Treatment
- Rectal Tumors
- Smart Watch
- Quality of Life (QOL)
Interventions
Utilizing a smartwatch to gather data on individuals receiving treatment for rectal neoplasm.Device
Employing a smartwatch to monitor steps, sleep quality, intense physical activity, and vital signs in persons undergoing treatment for rectal carcinoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of pathological complete response in rectal cancer patients receiving neoadjuvant therapyTime frame: 9 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Ankara University
Ankara, Turkey (Türkiye)
Etlik City Hospital
Ankara, Yenimahalle, Turkey (Türkiye)
Gazi University
Ankara, Yenimahalle, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.